CN1594362A - Yolk antibody specific for helicobacter pylori and its preparation and application - Google Patents
Yolk antibody specific for helicobacter pylori and its preparation and application Download PDFInfo
- Publication number
- CN1594362A CN1594362A CNA031508707A CN03150870A CN1594362A CN 1594362 A CN1594362 A CN 1594362A CN A031508707 A CNA031508707 A CN A031508707A CN 03150870 A CN03150870 A CN 03150870A CN 1594362 A CN1594362 A CN 1594362A
- Authority
- CN
- China
- Prior art keywords
- hen
- immunity
- antigen
- antibody
- egg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a yolk antibody specific for helicobacter pylori, its preparation and use thereof, wherein gene recombination HP specific proteantigens are employed to immune the oviposition hens, and composite vitelline antibodies (anti-HPSlgY) are extracted from the eggs. The invention can be applied to charge yolk powder containing composite vitelline antibodies into foodstuff or be used to prepare health food, can be used in the prevention and cure of diseases caused by Helicobacter pylori.
Description
Technical field
The present invention relates to a kind of antibody and application thereof, particularly relate to the preparation of the peculiar antigenic composite yolk antibody of a kind of anti-helicobacter pylori and in food, protective foods and application pharmaceutically.
Technical background
Nineteen eighty-two, Warren and Marshall are separated to a kind of new bacterium from the gastric biopsy of a duodenal ulcer patients, now be referred to as helicobacter pylori (Helicobacter pylori, be called for short HP), and to propose it be exactly the virulence factor of peptide ulceration.This hypothesis that studies confirm that through 14 years.In February, 1994, in the special meeting that NIH (NIH) is presided over, one independently panel of experts announce that peptide ulceration is an infectious diseases, suggestion substitutes in the past relieving haperacidity treatment with antibiotic therapy.
The helicobacter pylori infection extend over the entire globe, economically less developed region infection rate height, and increase progressively with age growth.The infection time length is also very long, even throughout one's life.The infection rate of developing country is higher than developed country, and the infection rate of China is about 70%.Often cause continuing the acute gastritis of several weeks to several months behind the helicobacter pylori infection, develop into chronic active gastritis then, it often continues throughout one's life.The metainfective several years to many decades, chronic gastritis can be asymptomatic, also can develop into peptide ulceration, atrophic gastritis even cancer of the stomach.Studies show that the duodenal ulcer more than 90%, the stomach ulcer more than 70% is by due to the helicobacter pylori infection, and the generation of cancer of the stomach is also relevant with helicobacter pylori infection.
Helicobacter pylori infection generally adopts antibiotic therapy at present, and routine is a triple therapy, is no more than 14 days the course of treatment.But there are many shortcomings in antibiotic therapy, and is big as growing toxic side effect the course of treatment, because of the generation of drug-fast helicobacter pylori is infected easily repeatedly.Therefore, the world of medicine is all seeking more thorough more effective solution, as biotherapy means such as vaccine and antibody.
Immunoglobulin of Yolk G antibody is a kind of 7S immunoglobulin. slightly different with Mammals IgG.This protein molecular weight is about 180kDa, contains two subunits, and promptly the light chain of the heavy chain of 67-70kDa and 22-30kDa claims IgY (Yolk Immlmoglobulin) again, is present in the yolk of immunity back hen.Experimental results show that.After being subjected to immunostimulation, hen produces immune response, and in the yolk ripening stage in uterine tube, IgG can optionally be transferred in the yolk in the blood, and is immunoglobulins unique in the yolk.
Acidproof, the heat-resisting and stable performance because of IgY antibody, but oral administration is used to prevent or treat young animal or human infectious intestinal disease, as baby's diseases prevention food, the prevention of dental caries, the prevention of newborn sucking pig lethality coli-infection, and the fish disease treatment etc.When particularly the use of microbiotic or other medicines had problems, IgY became first-selection.Farrely etc. prevent the rabbit dysentery with the special village of enterotoxigenic E immunity preparation Y antibody oral administration.Wherein serious diarrhoea all takes place in negative control group in the 72h after attacking with enterotoxigenic E; Experimental group began to feed in attack in preceding 4 days raises yolk, does not see obvious adverse reaction after the attack.Experiment shows that also normal yolk has the part provide protection: 4 rabbit feed with normal yolk, and wherein 3 are developed into moderate diarrhoea, and 1 normal fully, do not fall ill.This research group has also carried out experiment in vitro, shows 1, and IgY disturbs the mucous membrane of small intestine protein binding of E.coli and purification; 2, this interference effect of IgY is better than chicken serum IgG antibody.Yokoyama etc. have carried out the anti-infectious protectiveness test of IgY oral administration.4 age in days new calves per oral inoculation lethality salmonella typhis, and in that to begin to give IgY on the same day oral serve on 7-10 days 3 times every day.Control calves is all dead as a result, low dosage IgY group mortality ratio 60%-100%, and heating or diarrhoea only appear in none death of high dose group, successfully infect with the anti-calf lethality of IgY Salmonella typhimurium mattress.Robert successfully suppresses the rotavirus growth that histocyte is cultivated with yolk and extract thereof.In the infection animal experimental model, special IgY can prevent that animal from developing into rotaviral gastroenteritis, shows that yolk extract can be used as the antiviral antibody source, the control infantile rotavirus enteritis.
The research for preparing IgY with the HP immunization laying hen also has a small amount of report, but their the used antigen full bacterium antigen that is HP or slightly carry antigen, and poor specificity consequently is easy to the human intestinal normal microflora after oral and reacts, and causes the intestinal microflora disruption of ecological balance.
The content of invention
One of technical problem to be solved by this invention is: overcome the deficiencies in the prior art, provide a kind of composite yolk antibody that contains the peculiar proteantigen of anti-helicobacter pylori (HP) (anti---egg HPSlgY).
Two of technical problem to be solved by this invention is: provide the above-mentioned composite yolk antibody that contains the peculiar proteantigen of anti-helicobacter pylori (HP) (anti---the HPSlgY) production method of egg.
Three of technical problem to be solved by this invention is: overcome the deficiencies in the prior art, provide the peculiar proteantigen of a kind of anti-HP composite yolk antibody (anti---HPSlgY).
Four of technical problem to be solved by this invention is: provide above-mentioned anti---the production method of HPSlgY.
Five of technical problem to be solved by this invention is: the above-mentioned application of egg in food, foodstuff additive, medicine, protective foods and diagnosis that contains the composite yolk antibody of the peculiar proteantigen of anti-HP is provided.
Six of technical problem to be solved by this invention is: provide above-mentioned anti---the application of HPSlgY in food, foodstuff additive, medicine, protective foods and diagnosis.
The technical scheme that the present invention one of solves the problems of the technologies described above is: and a kind of composite yolk antibody that contains the peculiar proteantigen of anti-helicobacter pylori (HP) (anti---egg HPSlgY), described egg are to descend the egg that laying hen produced with the immunity of HP complex antigen.Its production is to finish as follows: (1) adopts the distinctive proteantigen of genetically engineered recombinant methods HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity.
Two the technical scheme that the present invention solves the problems of the technologies described above is: contain the peculiar proteantigen of anti-helicobacter pylori (HP) composite yolk antibody (anti---the HPSlgY) production method of egg, its production method comprise the steps: that (1) adopt the distinctive proteantigen of genetically engineered recombinant methods HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity.
The distinctive proteantigen of described HP comprises: urease B subunit (urease β-subunit, UreB), heat shock protein(HSP) 60 (heat-shock protein 60, Hsp60), cytotoxin-associated protein A (Cytotoxin associated gene A, CagA), vacuolate cytotoxin A albumen (vacuolating cytotoxin A, VacA).The distinctive proteantigen of described HP is to adopt the genetically engineered recombination method to obtain.
Three the technical scheme that the present invention solves the problems of the technologies described above is: and the composite yolk antibody of the distinctive proteantigen of a kind of anti-HP (anti---HPSlgY), described antibody only plays antigen antibody reaction with HP or the distinctive antigen of HP, and not with human intestinal normal microflora or its antigen play antigen antibody reaction.Its preparation method comprises the steps: the distinctive proteantigen of (1) employing genetically engineered recombinant methods HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity; (4) separation and purification antibody from the immune egg Huang.
Four the technical scheme that the present invention solves the problems of the technologies described above is: anti---the production method of HPSlgY, its preparation method comprise the steps: that (1) adopt gene engineering method to prepare the distinctive proteantigen of HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity; (4) separation and purification antibody from the immune egg Huang.
The above-mentioned composite yolk antibody that contains the peculiar proteantigen of anti-HP provided by the present invention (anti---HPSlgY) egg and anti--HPSlgY antibody can be widely used in food, foodstuff additive, medicine and the protective foods, and the relative disease that the control helicobacter pylori infection is caused has good effect.Because the immunity used antigen of laying hen down is to adopt the genetically engineered recombination method to obtain, and be that HP is distinctive, compared with prior art, advantage of the present invention is: specificity is good, be that described antibody only plays antigen antibody reaction with HP, thereby play the effect of killing HP or stoping HP to infect, and can not play destruction the normal microflora of human intestinal.To adopt ovum gallinaceum that hen produces be carrier in the present invention in addition, and safety non-toxic is easy to industrialization, and cost is low.
Embodiment
Be further described of the present invention below in conjunction with embodiment:
Embodiment 1: and the composite yolk antibody of the distinctive proteantigen of anti-HP (anti---HPSlgY) can obtain by following steps: (1) adopts gene engineering method to prepare the distinctive proteantigen of HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity; (4) separation and purification antibody from the immune egg Huang.
Embodiment 2: use the distinctive proteantigen of genetically engineered recombinant methods HP: infect male stomach ulcer patient gripping mucosa tissue with gastroscope from HP, coating HP selects to cultivate on the brucella agar plate, 37 ℃ of little aerobic cultivations 5 days, collect bacterium colony, the DNA of ordinary method extracting HP, the UreB of pcr amplification HP, Hsp60, CagA, the VacA gene, with above-mentioned 4 gene clones in colibacillus expression plasmid, the recombinant plasmid transformed intestinal bacteria, the fermentation recombination bacillus coli is with the UreB in the chromatography purification intestinal bacteria, Hsp60, CagA, VacA albumen.
Embodiment 3: the immunity hen that lays eggs: select the health hen isolated rearing of laying eggs in 10 ages in week for use, carry out injection under the cock skin, every hen injection point is 2, immunity is 100 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is 100 μ g antigens, after the first immunisation, per two all booster immunizations once amount to immunity 8 times;
Embodiment 4: the immunity hen that lays eggs: select the health hen isolated rearing of laying eggs in 40 ages in week for use, carry out injection under the cock skin, every hen injection point is 8, immunity is 500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is 600 μ g antigens, after the first immunisation, per two all booster immunizations once amount to immunity 8 times;
Embodiment 5: the immunity hen that lays eggs: select the health hen isolated rearing of laying eggs in 30 ages in week for use, carry out injection under the cock skin, every hen injection point is 4, immunity is 200 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is 400 μ g antigens, after the first immunisation, per two all booster immunizations once amount to immunity 8 times;
Embodiment 6: separate yolk from immune egg: collection contains anti---HPSlgY immunity egg, separate yolk, and spraying drying must contain the yolk powder of anti--HPSlgY.
Embodiment 7: antibody purification: collection contains anti---HPSlgY immunity egg, separate yolk and with 10 times water dissolution, regulate pH value to 5.0, placed 8 hours for 4 ℃, precipitation promptly obtains Ovum Gallus domesticus Flavus water-soluble portion (WSF) after removing lipoprotein, is 40% ammonium sulfate precipitation with concentration, an amount of physiological saline solution of throw out, and in physiological saline, dialysed 24 hours, lyophilize is promptly resisted-HPSlgY.
Embodiment 8: get that any product carries out the IgY titration among the embodiment 1,6,7: adopt simple immunodiffusion method to carry out the IgY titration, it is 1 that IgY tires: 512-1: 32768.
Embodiment 9: add the yolk powder that 10 grams contain anti--HPSlgY in per 100 gram milk powder, products obtained therefrom can be used for the infant and adult's prevention HP infects, or the assisting therapy that has infected the patient of HP.
Embodiment 10: add the anti--HPSlgY lyophilized powder of 1 gram purifying in per 100 gram milk powder, products obtained therefrom can be used for the infant and adult's prevention HP infects, or the assisting therapy that has infected the patient of HP.
Embodiment 11: add the anti--HPSlgY lyophilized powder of 1 gram purifying in every 100ml fresh milk, products obtained therefrom can be used for the infant and adult's prevention HP infects, or the assisting therapy that has infected the patient of HP.
Embodiment 12: anti--HPSlgY lyophilized powder and hericium erinaceum polysaccharide are pressed 1: 5 mixed, and the can capsule can be used for protecting the protective foods of stomach mucous membrane.
Embodiment 13: anti--HPSlgY lyophilized powder adds pharmaceutical adjunct, and the can capsule can be used for treating the medicine that HP infects.
Claims (9)
1, a kind of composite yolk antibody that contains the peculiar proteantigen of anti-helicobacter pylori (HP) (anti--HPSlgY) egg, it is characterized in that described egg is to descend the egg that laying hen produced with the immunity of HP complex antigen.
2, egg according to claim 1 is characterized in that, its production method comprises the steps: the distinctive proteantigen of (1) employing genetically engineered recombinant methods HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity.
3, method according to claim 2, it is characterized in that, the distinctive proteantigen of described HP comprises: urease B subunit (urease β-subunit, UreB), heat shock protein(HSP) 60 (heat-shock protein60, Hsp60), cytotoxin-associated protein A (Cytotoxin associated gene A, CagA), vacuolate cytotoxin A albumen (vacuolating cytotoxin A, VacA).
4, method according to claim 2 is characterized in that, the distinctive proteantigen of described HP is to adopt the genetically engineered recombination method to obtain.
5, the composite yolk antibody of the distinctive proteantigen of a kind of anti-HP (anti---HPSlgY), it is characterized in that described antibody only plays antigen antibody reaction with HP or the distinctive antigen of HP, and do not play antigen antibody reaction with normal microflora or its antigen of human intestinal.
6, antibody according to claim 5 is characterized in that, described antibody capable plays special antigen antibody reaction with UreB, Hsp60, CagA, the VacA antigen of HP specifically.
7, antibody according to claim 5 is characterized in that, its preparation method comprises the steps: that (1) employing gene engineering method prepares the distinctive proteantigen of HP; (2) the immunity hen that lays eggs: select the hen isolated rearing of laying eggs of 10-40 (30) health in age in week for use, carry out injection under the cock skin, every hen injection point is 2-8, immunity is 100-500 μ g/ml (200) with antigen concentration, and adding the equivalent freund adjuvant, every each immunizing dose of hen is a 100-600 μ g antigen, after the first immunisation, per two all booster immunizations once amount to immunity 8 times; (3) collect the egg that is produced after the last immunity; (4) separation and purification antibody from the immune egg Huang.
8, the described egg of claim 1 is in following field but the application in being not limited to: food, foodstuff additive, medicine, protective foods and diagnosis.
9, the described antibody of claim 5 is in following field but the application in being not limited to: food, foodstuff additive, medicine, protective foods and diagnosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031508707A CN1594362A (en) | 2003-09-09 | 2003-09-09 | Yolk antibody specific for helicobacter pylori and its preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031508707A CN1594362A (en) | 2003-09-09 | 2003-09-09 | Yolk antibody specific for helicobacter pylori and its preparation and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1594362A true CN1594362A (en) | 2005-03-16 |
Family
ID=34659765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031508707A Pending CN1594362A (en) | 2003-09-09 | 2003-09-09 | Yolk antibody specific for helicobacter pylori and its preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1594362A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101905018A (en) * | 2010-04-06 | 2010-12-08 | 中国人民解放军第三军医大学 | Recombinant fusion protein vaccine and attenuated live vector vaccine for treating and preventing helicobacter pylori (Hp) infection |
| CN101411362B (en) * | 2008-10-14 | 2012-05-30 | 大连韩伟企业集团有限公司 | Yoghourt containing vitellus immunoglobulin with helicobacter pylori resistance |
| CN105367659A (en) * | 2015-11-18 | 2016-03-02 | 李昕阳 | Preparation method and application of urease activity inhibition yolk antibody |
| CN106310251A (en) * | 2016-08-23 | 2017-01-11 | 河北中贝佳美生物科技有限公司 | Anti-virus and IgY antibody improving chicken formula and preparing method thereof |
| CN108531468A (en) * | 2018-02-24 | 2018-09-14 | 广东工业大学 | Encode gene, Yolk antibody and the application of recombinant helicobacterpylori serine protease |
| CN109503710A (en) * | 2018-11-21 | 2019-03-22 | 浙江蓝盾药业有限公司 | Helicobacter pylori resistant Yolk antibody and the preparation method and application thereof |
| CN110467673A (en) * | 2018-05-10 | 2019-11-19 | 北京万华生物工程有限公司 | It is a kind of remove gastrointestinal tract helicobacter pylori substance and application |
| CN111793137A (en) * | 2019-12-12 | 2020-10-20 | 南京蛋球球生物医学技术合伙企业(有限合伙) | Hp tetravalent antigen and preparation method and application thereof |
| CN113845590A (en) * | 2021-10-19 | 2021-12-28 | 大连先锋生物科技有限公司 | Block chain-based helicobacter pylori egg yolk antibody and preparation method thereof |
| WO2023029666A1 (en) * | 2021-09-06 | 2023-03-09 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori composite antigen, antibody, preparation method and use |
| CN116854814A (en) * | 2023-07-05 | 2023-10-10 | 江苏润洁生物科技有限公司 | Preparation method and application of helicobacter pylori egg yolk antibody |
-
2003
- 2003-09-09 CN CNA031508707A patent/CN1594362A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411362B (en) * | 2008-10-14 | 2012-05-30 | 大连韩伟企业集团有限公司 | Yoghourt containing vitellus immunoglobulin with helicobacter pylori resistance |
| CN101905018B (en) * | 2010-04-06 | 2013-04-24 | 中国人民解放军第三军医大学 | Recombinant fusion protein vaccine and attenuated live vector vaccine for treating and preventing helicobacter pylori (Hp) infection |
| CN101905018A (en) * | 2010-04-06 | 2010-12-08 | 中国人民解放军第三军医大学 | Recombinant fusion protein vaccine and attenuated live vector vaccine for treating and preventing helicobacter pylori (Hp) infection |
| CN105367659A (en) * | 2015-11-18 | 2016-03-02 | 李昕阳 | Preparation method and application of urease activity inhibition yolk antibody |
| CN106310251A (en) * | 2016-08-23 | 2017-01-11 | 河北中贝佳美生物科技有限公司 | Anti-virus and IgY antibody improving chicken formula and preparing method thereof |
| CN108531468B (en) * | 2018-02-24 | 2020-07-17 | 广东工业大学 | Gene for coding recombinant helicobacter pylori hypha ammonia protease, yolk antibody and application |
| CN108531468A (en) * | 2018-02-24 | 2018-09-14 | 广东工业大学 | Encode gene, Yolk antibody and the application of recombinant helicobacterpylori serine protease |
| CN110467673A (en) * | 2018-05-10 | 2019-11-19 | 北京万华生物工程有限公司 | It is a kind of remove gastrointestinal tract helicobacter pylori substance and application |
| CN109503710A (en) * | 2018-11-21 | 2019-03-22 | 浙江蓝盾药业有限公司 | Helicobacter pylori resistant Yolk antibody and the preparation method and application thereof |
| CN111793137A (en) * | 2019-12-12 | 2020-10-20 | 南京蛋球球生物医学技术合伙企业(有限合伙) | Hp tetravalent antigen and preparation method and application thereof |
| WO2023029666A1 (en) * | 2021-09-06 | 2023-03-09 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori composite antigen, antibody, preparation method and use |
| CN113845590A (en) * | 2021-10-19 | 2021-12-28 | 大连先锋生物科技有限公司 | Block chain-based helicobacter pylori egg yolk antibody and preparation method thereof |
| CN116854814A (en) * | 2023-07-05 | 2023-10-10 | 江苏润洁生物科技有限公司 | Preparation method and application of helicobacter pylori egg yolk antibody |
| CN116854814B (en) * | 2023-07-05 | 2024-03-26 | 江苏润洁生物科技有限公司 | Preparation method and application of helicobacter pylori egg yolk antibody |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Korhonen et al. | Bovine milk antibodies for health | |
| Gadde et al. | Passive immunization with hyperimmune egg-yolk IgY as prophylaxis and therapy for poultry diseases–a review | |
| US7355092B2 (en) | Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens | |
| Yegani et al. | Application of egg yolk antibodies as replacement for antibiotics in poultry | |
| CN1594362A (en) | Yolk antibody specific for helicobacter pylori and its preparation and application | |
| TW200410712A (en) | Anti-chicken coccidiosis composition | |
| FI108775B (en) | Process for the preparation of a vaccine composition against intestinal infection caused by the bacterium E. coli in man | |
| KR100267747B1 (en) | Complex immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli or porcine epidemic diarrhea virus | |
| AU696237B1 (en) | Prevention and treatment of enterohemorrhagic E.Coli infection | |
| US20210252148A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| CN1191075C (en) | Composition and method for increasing weight gain and feed efficiency | |
| KR100267746B1 (en) | Oral immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli | |
| KR20090016236A (en) | Bovine disease of antigen manufacturing process and immune antibody(igy, colostrum) production and composition for add electrolyte prevent diarrhea in calf | |
| CN1593169A (en) | Specific anti-helicobacter pylori immunological cow foremilk preparation method and its uses | |
| JP2010065010A (en) | Composition for preventing and/or treating gastritis, gastric ulcer and/or duodenal ulcer, and food/drink containing the same | |
| Majumder et al. | Egg Yolk Antibody Farming for Passive Immunotherapy | |
| KR101496937B1 (en) | Method for Separating Yolk Antibody against Pili Antigen of E. coli or Flagella Protein Antigen of Salmonella sp. | |
| CN1297315C (en) | Preparation method of anti prglet bacterial epidemic disease compound egg antibody medicinal preparation | |
| CN116139263A (en) | Pig enterovirus composite vaccine and preparation method thereof | |
| CN118048275A (en) | Bacillus subtilis and application thereof in improving animal immunity | |
| Barbour et al. | Quantitative assessment of humoral immunosuppression in water deprived semi nomadic sheep | |
| JPS6289625A (en) | Treatment for animal gastro-intestinal disease | |
| CN114073766A (en) | Helicobacter pylori epitope peptide and application thereof | |
| JP2002514604A (en) | Antidiarrheal drug and method for using it | |
| RU2287992C1 (en) | Method for immunoprophylaxis of viral respiratory diseases in calves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Xu Chundi Document name: Notice of first review |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |